首页|期刊导航|Virologica Sinica|Systematic evaluation of HSV-1 Δ34.5Δ47 as a dual-function platform for attenuated HSV-1 vaccine and heterologous antigen delivery

Systematic evaluation of HSV-1 Δ34.5Δ47 as a dual-function platform for attenuated HSV-1 vaccine and heterologous antigen deliveryOA

中文摘要

Herpes simplex virus type 1(HSV-1)causes lifelong latent infection and is associated with severe diseases,including herpes simplex encephalitis,neonatal herpes,and no licensed vaccine is currently available for this pathogen.Here,we systematically evaluated an attenuated HSV-1 platform with deletions in ICP34.5 and ICP47 genes(HSV-1Δ34.5Δ47)for application as a dual-function vaccine.This construct,generated by BAC-galK recombination,showed attenuated replication in vitro.Notably,it elicited robust humoral and cellular immune responses in mice,and provided complete protection against lethal challenge with virulent HSV-1 McKrae strain through both corneal and genital tract infection routes.To assess its utility for heterologous antigen delivery,we engineered a recombinant HSV-1Δ34.5Δ47-N,which expresses the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)nucleocapsid(N)protein.This recombinant virus retained the protective efficacy against HSV-1 and induced robust N-specific immune responses.Passive serum transfer and in vivo T-cell depletion studies demonstrated that humoral immunity was sufficient to mediate protective immunity against HSV-1 challenge.Safety assessment revealed no detectable viral mRNA or pathological lesions in the brains of immunized animals.These findings support HSV-1Δ34.5Δ47 as a safe and versatile platform for both HSV-1 prophylaxis and heterologous antigen delivery.

Ziyu Wen;Haohang Wang;Yu Liao;Shunran Li;Minjuan Shi;Mingting Cui;Jun Qian;Caijun Sun

School of Public Health(Shenzhen),Sun Yat-sen University,Shenzhen 518107,ChinaSchool of Public Health(Shenzhen),Sun Yat-sen University,Shenzhen 518107,ChinaSchool of Public Health(Shenzhen),Sun Yat-sen University,Shenzhen 518107,ChinaSchool of Public Health(Shenzhen),Sun Yat-sen University,Shenzhen 518107,ChinaSchool of Public Health(Shenzhen),Sun Yat-sen University,Shenzhen 518107,ChinaSchool of Public Health(Shenzhen),Sun Yat-sen University,Shenzhen 518107,ChinaSchool of Public Health(Shenzhen),Sun Yat-sen University,Shenzhen 518107,China Key Laboratory of Tropical Disease Control(Sun Yat-sen University),Ministry of Education,Guangzhou 510080,China Shenzhen Key Laboratory of Pathogenic Microbes and Biosafety,Shenzhen Campus of Sun Yat-sen University,Shenzhen 518107,China State Key Laboratory of Anti-Infective Drug Discovery and Development,School of Pharmaceutical Sciences,Sun Yat-sen University,Guangzhou 510080,ChinaSchool of Public Health(Shenzhen),Sun Yat-sen University,Shenzhen 518107,China Key Laboratory of Tropical Disease Control(Sun Yat-sen University),Ministry of Education,Guangzhou 510080,China Shenzhen Key Laboratory of Pathogenic Microbes and Biosafety,Shenzhen Campus of Sun Yat-sen University,Shenzhen 518107,China State Key Laboratory of Anti-Infective Drug Discovery and Development,School of Pharmaceutical Sciences,Sun Yat-sen University,Guangzhou 510080,China

医药卫生

Herpes simplex virus type 1(HSV-1)Attenuated vaccineViral vectorHumoral immunitySARS-CoV-2

《Virologica Sinica》 2026 (1)

P.196-207,12

supported by the National Natural Science Foundation of China(82472267,82271786 to C.S.)the Prevention and Control of Emerging and Major Infectious Diseases-National Science and Technology Major Project of China(2025ZD01904500,2025ZD01904501 to C.S.)the Science and Technology Planning Project of Guangdong Province,China(2021B1212040017 to C.S.)the Shenzhen Science and Technology Program(ZDSYS20230626091203007 to C.S.)the High-level project of Medicine in Nanshan,Shenzhen(SZSM202103008 to C.S.).

10.1016/j.virs.2026.01.002

评论